Rome Therapeutics Secures $77 Million In Series B Financing To Advance Repeatome-Derived Pipeline For Cancer And Autoimmune Diseases And Expand Repeatomics Platform
Rome Therapeutics Secures $77 Million In Series B Financing To Advance Repeatome-Derived Pipeline For Cancer And Autoimmune Diseases And Expand Repeatomics Platform
09/14/21, 10:37 AM
Location
cambridgeMoney raised
$77 million
Round Type
series b
ROME Therapeutics, a biotechnology company harnessing the power of the repeatome for drug development, today announced the completion of a $77 million Series B financing led by new investor Section 32. In addition, new investors Sanofi Ventures, Casdin Capital, Andreessen Horowitz and Alexandria Venture Investments participated in the round, alongside existing investors ARCH Ventures, GV and Mass General Brigham Ventures (formerly Partners Innovation Fund). Concurrent with the financing, Steven J. Kafka, Ph.D., managing partner at Section 32, and Jim Trenkle, Ph.D., head of investments at Sanofi Ventures, were appointed to ROME’s Board of Directors.